The Exelixis Discovery group is responsible for the identification of high quality small molecule development candidates suitable for advancement into our clinical development pipeline. The department consists of a highly integrated team of biologists and medicinal chemists, supported by external resources, who drive a process that starts with target selection and includes lead identification and verification, lead optimization and extensive pharmacological characterization. The group builds on Exelixis’ extensive drug discovery experience and assets, such as our unique compound library, while incorporating cutting edge technologies and approaches.

Other Departments